Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
Center for Biologics Evaluation and Research
Indexed incrossrefpubmed
Abstract
As of December 31, 2023, the FDA had become aware of 22 cases of T-cell cancers that occurred after treatment with CAR-T products. For now, such cancers appear to be relatively rare adverse events.
Citation impact
253
total citations
- FWCI
- 63.42
- Percentile
- 100%
- References
- 3
Citations per year
Authors
2Topics & keywords
Topics
Keywords
- Chimeric antigen receptor
- Medicine
- Adverse effect
- Antigen
- Receptor
- Cancer research
- Oncology
- Immunotherapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.